Isatuximab-irfc
Brand names: Sarclisa Escena · Active ingredient: Isatuximab
In short: SARCLISA ESCENA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the
What is Isatuximab-irfc used for?
SARCLISA ESCENA is indicated:
in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor.
in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
Isatuximab-irfc dosage
SARCLISA ESCENA and intravenous isatuximab-irfc have different dosage and administration instructions
.
SARCLISA ESCENA is for subcutaneous use only.
Check the product label to ensure that the correct formulation (SARCLISA ESCENA or intravenous isatuximab-irfc) is being prescribed and administered.
Administer premedications before SARCLISA ESCENA administration
.
SARCLISA ESCENA should be administered by a health care professional
.
Patients currently receiving intravenous isatuximab-irfc may transition to SARCLISA ESCENA solution for injection after the completion of the first cycle.
The recommended dose of SARCLISA ESCENA is 1,400 mg administered as a subcutaneous injection with the CirCLIQ On-Body Delivery System (OBDS) or with a syringe and infusion set for manual administration, in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone, or in combination with bortezomib, lenalidomide, and dexamethasone.
SARCLISA ESCENA dosing schedules are provided in Tables 1 and 2
.
Cycles | Dosing schedules
Cycle 1 (28-day cycle) | Days 1, 8, 15, and 22 (weekly)
Cycle 2 and beyond (28-day cycles) | Days 1 and 15 (every 2 weeks)
Cycles | Dosing schedule
Cycle 1 (28-day cycle) | Days 1, 8, 15, 22 (weekly)
Cycles 2 to 12 (28-day cycles) | Days 1 and 15 (every 2 weeks)
Cycles 13 and beyond (28-day cycles) | Day 1 (every 4 weeks)
Treatment is repeated until disease progression or unacceptable toxicity.
SARCLISA ESCENA is used in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone or in combination with bortezomib, lenalidomide, and dexamethasone. For dosing instructions of combination agents administered with SARCLISA ESCENA, see
Clinical Studies (14)
and manufacturer's prescribing information.
Missed SARCLISA ESCENA Doses
If a planned dose of SARCLISA ESCENA is missed, administer the dose as soon as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.
Recommended Premedications
Administer the following premedications 15 to 60 minutes prior to SARCLISA ESCENA administration to reduce the risk and severity of systemic administration reactions
:
When administered in combination with SARCLISA ESCENA and pomalidomide:
Dexamethasone 40 mg orally or intravenously (or 20 mg orally or intravenously for patients 75 years of age or older).
When administered in combination with SARCLISA ESCENA and carfilzomib:
Dexamethasone 20 mg orally or intravenously.
When administered in combination with SARCLISA ESCENA, bortezomib, and lenalidomide:
Dexamethasone 20 mg orally.
Leukotriene receptor antagonist, at cycle 1 only (Days 1, 8, 15, and 22).
Acetaminophen 650 mg to 1,000 mg orally. …
How to take Isatuximab-irfc — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Systemic Administration Reactions
Advise patients to seek immediate medical attention for any of the following signs and symptoms of systemic administration reaction: shortness of breath, wheezing or trouble breathing; swelling of the face, mouth, throat, or tongue; throat tightness; palpitations; dizziness, lightheadedness, or fainting; headache; cough; rash or itching; nausea; runny or stuffy nose; or chills
.
Neutropenia
Inform patients about the risk of neutropenia and infection during SARCLISA ESCENA treatment and the importance of reporting immediately any fever or symptoms of infection to their healthcare provider
.
Infections
Inform patients about the risk of developing infections during SARCLISA ESCENA treatment, and to report immediately any fever or symptoms of infection to their healthcare provider
.
Second Primary Malignancies
Inform patients of the risk of developing second primary malignancies during treatment with SARCLISA ESCENA when given with pomalidomide and dexamethasone or with carfilzomib and dexamethasone, or with bortezomib, lenalidomide, and dexamethasone
. …
Warnings & precautions
Do not take this medicine if: SARCLISA ESCENA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients
.
SARCLISA ESCENA can cause both systemic administration-related reactions (SARs), including severe or life-threatening reactions, and local injection-site reactions.
Systemic Administration Reactions
In a pooled safety population of 411 patients with multiple myeloma who received SARCLISA ESCENA in combination with pomalidomide and dexamethasone (Pd), with carfilzomib and dexamethasone (Kd), and with bortezomib, lenalidomide, and dexamethasone (VRd) (IRAKLIA, IZALCO, and IsaSoCut, respectively, N=411), SARs occurred in 3.2% (Grade 1: 2.2%, Grade 2: 0.7%, Grade 3: 0.2%) of patients. SARs occurred at the first administration in 1.9% of patients and at subsequent administrations in 1.5% of patients. The median time to onset was 4 hours (range: 12 minutes to 3 days). The most frequently reported symptoms of SARs (all below 1%) were pyrexia and dyspnea, and Grade ≥3 symptoms was dyspnea (not collected in IsaSoCut study)
. In multiple myeloma clinical trials with intravenous isatuximab-irfc, anaphylactic reactions occurred in <1% of patients.
To decrease the risk and severity of SARs, premedicate patients prior to SARCLISA ESCENA administration with leukotriene receptor antagonists (at cycle 1 only), acetaminophen, diphenhydramine, or equivalent, and dexamethasone
.
In case of grade 2 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. Administer additional premedication, as needed, for subsequent SARCLISA ESCENA administration. In case of grade 3 SAR during SARCLISA ESCENA administration, stop current administration and do not complete it. SARCLISA ESCENA administration may be resumed at the next planned administration. …
Isatuximab-irfc side effects
The following clinically significant adverse reactions from SARCLISA ESCENA are also described in other sections of the labeling:
Hypersensitivity and Other Administration Reactions
Neutropenia
Infections
Second Primary Malignancies
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed and/or Refractory Multiple Myeloma
Combination treatment with pomalidomide and dexamethasone (SARCLISA ESCENA-Pd versus intravenous isatuximab-irfc-Pd)
IRAKLIA
The safety of SARCLISA ESCENA was evaluated in IRAKLIA, a randomized, open-label phase 3 clinical trial in patients with previously treated multiple myeloma. Patients received SARCLISA ESCENA 1,400 mg administered subcutaneously, weekly in the first cycle and every two weeks thereafter, in combination with pomalidomide and dexamethasone (SARCLISA ESCENA-Pd, n=263) or isatuximab-irfc administered intravenously in combination with pomalidomide and dexamethasone (intravenous isatuximab-irfc-Pd, n=264)
. Among patients receiving SARCLISA ESCENA-Pd, 66% were exposed to SARCLISA ESCENA for 6 months or longer and 25% were exposed for greater than 12 months or longer. The median duration of the injection with OBDS was 13 minutes.
Serious adverse reactions occurred in 53% of patients receiving SARCLISA ESCENA-Pd. …
Drug interactions
Interference with Serological Testing
Isatuximab-irfc, an anti-CD38 antibody, may interfere with blood bank serologic tests with false positive reactions in indirect antiglobulin tests (indirect Coombs tests), antibody detection (screening) tests, antibody identification panels, and antihuman globulin crossmatches in patients treated with isatuximab-irfc
.
Interference with Serum Protein Electrophoresis and Immunofixation Tests
Isatuximab-irfc may be incidentally detected by serum protein electrophoresis and immunofixation assays used for the monitoring of M-protein and may interfere with accurate response classification based on International Myeloma Working Group (IMWG) criteria
. Because of this interference, Hydrashift assay was routinely used in IRAKLIA and IZALCO clinical studies for efficacy assessment to determine the complete response in patients with IgG kappa myeloma protein. In patients with persistent very good partial response, where interference is suspected, consider using an FDA-cleared isatuximab-irfc-specific IFE assay to distinguish isatuximab-irfc from any remaining endogenous M-protein in the patient's serum to facilitate determination of a complete response.
About this medicine
Isatuximab-irfc, a CD38-directed cytolytic antibody, is a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (mAb). Isatuximab-irfc is produced from a mammalian cell line (Chinese hamster ovary, CHO) using a fed-batch production process. Isatuximab-irfc is composed of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains and has an overall molecular weight of approximately 148 kDa.
SARCLISA ESCENA (isatuximab-irfc) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, in a single-dose vial for subcutaneous use. Each vial contains 1,400 mg/10 mL at a concentration of 140 mg/mL with a pH of 6.2. Each mL of solution contains 140 mg isatuximab-irfc, arginine hydrochloride (23.2 mg), histidine (0.82 mg), histidine hydrochloride monohydrate (0.78 mg), poloxamer 188 (4.0 mg), sucrose (20.0 mg), and Water for Injection, USP. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 07730e8c-1340-4d30-8d71-e20f850db8da. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate